HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA First Amendment Application Guidelines Urged By CTFA

This article was originally published in The Rose Sheet

Executive Summary

FDA should develop guidelines laying out a First Amendment analysis that would be applied prior to any curtailment of marketing "speech" and followed "consistently throughout the agency," the Cosmetic, Toiletry and Fragrance Association asserts in Oct. 28 comments

You may also be interested in...



Cosmetic Claims “Misleading” Standard Should Be Articulated By FDA – CTFA

FDA's development of a general policy statement on how it determines whether labeling claims for cosmetics and cosmetic-drugs are "inherently misleading" is urged by the Cosmetic, Toiletry and Fragrance Association in Sept. 13 comments to the agency

FDA Commercial Speech Regs Constitutionality Debate Opened By Agency

FDA invites public comments on the constitutionality of its approach to regulating advertising and marketing practices for cosmetics, drugs and other products in a notice appearing in the May 16 Federal Register

Sunscreen, OTC Labeling Reg First Amendment Intrusions Cited By CTFA

FDA's sunscreen and OTC labeling final regs will have difficulty passing constitutional muster in light of a recent court decision requiring agency-drafted disclaimers for a folic acid health claim, the Cosmetic, Toiletry and Fragrance Association maintains.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010719

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel